https://bbwpublisher.com/index.php/OTD <p><em>Oncology Treatment Discovery</em>&nbsp;is a peer-reviewed, open access journal. It accepts manuscripts relevant to experimental and clinical cancer research. The journal publishes the latest findings in cancer research, including preliminary results, repeated argumentation studies and negative results. The journal welcomes various types of submissions, e.g. research papers, clinical research reports, review articles. Content covers topics that advance clinical practice, challenge the status quo, advocate change in health policy,<strong>&nbsp;</strong>genomic instability, growth promoting signals, growth inhibitory signals,&nbsp;cell death, tumour microenvironment, carcinogenesis and cancer prevention&nbsp;and tackle issues related to global oncology.</p> Bio-Byword Scientific Publishing PTY LTD en-US Oncology Treatment Discovery 3083-4996 https://bbwpublisher.com/index.php/OTD/article/view/12045 <p><em>Objective</em>: To explore the clinical application of endoscopic esophageal dilation combined with mitomycin in the treatment of corrosive esophageal stenosis in children. <em>Methods</em>: Twenty children with corrosive esophageal stenosis treated in our hospital from August 2023 to March 2025 were selected and divided into an intervention group (<em>n</em> = 10, combined with mitomycin) and a control group (<em>n</em> = 10, simple dilation) according to the treatment plan. The Stooler swallowing grade, diameter of the stenotic segment, total effective rate, number of dilations, and complications were compared between the two groups before and after treatment. <em>Results</em>: After treatment, the swallowing function improved in both groups, but the increase in the diameter of the stenotic segment was greater in the intervention group (<em>P</em> &lt; 0.05), and the total effective rate was higher (<em>P</em> &lt; 0.05). The average number of dilations in the intervention group (3.20 ± 1.03) was significantly less than that in the control group (5.00 ± 1.63) (<em>P</em> &lt; 0.05). There was no statistical difference in the incidence of complications between the two groups, mainly mild bleeding and chest pain. <em>Conclusion</em>: Combined mitomycin can improve efficacy, reduce treatment frequency, and has good safety, which is worthy of priority clinical application.</p> Shiwu Yang Junru Chen Jun Wu Fenglong He Mingxiang Zhang Copyright (c) 2025 Author(s) 2025-09-17 2025-09-17 3 3 1 8 10.26689/otd.v3i3.12045